Ekso Bionics’ CEO Provides Update on Magnitude of Stroke Rehabilitation Market on CNBC’s “On the Money”
May 15 2017 - 8:00AM
Thomas Looby, President and Chief Executive Officer of Ekso Bionics
Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company
delivering solutions for medical and industrial markets, provided
an update on the stroke rehabilitation market. Addressing the
stroke market is a unique opportunity for Ekso Bionics to create a
new standard of care focusing on issues such as cost of care,
safety of care-workers, and length of stay, while simultaneously
building a long-term sustainable business model.
The interview, which aired on CNBC’s “On the
Money” with Becky Quick, can be viewed here: Ekso on CNBC Becky
Quick
“To meet global demands for quality, efficiency and performance,
companies around the world continue to integrate robotic
technologies into their processes. Healthcare is no
exception as robot-assisted surgery has become the standard of care
for some procedures. In the area of stroke rehabilitation, there is
a need to ignite patient neuroplasticity through repetitive motion
and the Ekso GT technology is ideally positioned to meet that
demand,” said Thomas Looby, President and Chief Executive Officer
of Ekso Bionics.
“Being the first in a new category means charting new territory
with limited visibility on the pace of adoption and the ideal mix
of sales versus rentals. We believe that we have the best and
smartest medical device on the market for our clinical customers
with the broadest FDA approval in the industry. We remain
confident in our ability to deliver on the promise of expanding the
use of robotic exoskeletons across industries. We have clear
objectives for our businesses, are closely monitoring key metrics
and will aggressively act to course correct as needed,” added
Looby.
About Ekso Bionics® Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) estimates or
projection of financial results, financial condition, capital
expenditures, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not meant
to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
Media Contact:
Carrie Yamond
212-867-1788
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024